Trial | NCT00703235  Report issue

Title

Intravitreal Bevacizumab for Diabetic Macular Edema

  • Phase

    Phase 2/Phase 3

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    None
Diabetic macular edema is a common cause of visual loss among diabetic patients. Studies have demonstrated the role of vascular endothelial growth factor (VEGF) in the pathogenesis of edema.

This study designed to evaluate the effect of Intravitreal injection of a recombinant monoclonal anti-VEGF antibody, Bevacizumab, for treatment of diabetic macular edema.
Study Started
Jun 20
2008
Last Update
Jun 23
2008
Estimate

Drug Bevacizumab

Criteria 

Inclusion Criteria:

Diabetes mellitus
Clinically significant macular edema
Possibility of performing macular OCT
Consent of patient for inclusion in the study

Exclusion Criteria:

History of macular photocoagulation in less than 6 months of inclusion in the study
Necessity of surgical intervention
Rejection of the remaining in the study by patient
No Results Posted